Sensus Healthcare (NASDAQ:SRTS) Price Target Lowered to $13.00 at Lake Street Capital

Sensus Healthcare (NASDAQ:SRTS) had its target price cut by equities research analysts at Lake Street Capital from $18.00 to $13.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s target price indicates a potential upside of 196.47% from the stock’s current price.

Several other research analysts have also recently commented on SRTS. HC Wainwright upped their target price on shares of Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Maxim Group increased their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS traded up $0.04 during mid-day trading on Tuesday, hitting $4.39. The company had a trading volume of 60,184 shares, compared to its average volume of 367,445. The stock has a market cap of $72.33 million, a price-to-earnings ratio of 10.94 and a beta of 1.28. The firm’s 50 day simple moving average is $6.23 and its two-hundred day simple moving average is $6.71. Sensus Healthcare has a 12 month low of $2.91 and a 12 month high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. Equities analysts forecast that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SRTS. Renaissance Technologies LLC increased its position in shares of Sensus Healthcare by 5.3% during the 4th quarter. Renaissance Technologies LLC now owns 430,934 shares of the company’s stock valued at $2,982,000 after purchasing an additional 21,600 shares during the period. Dimensional Fund Advisors LP boosted its stake in Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock valued at $2,620,000 after buying an additional 88,953 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock worth $1,039,000 after acquiring an additional 67,269 shares during the period. Geode Capital Management LLC raised its position in Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after acquiring an additional 11,525 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in Sensus Healthcare by 99.6% in the 4th quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock valued at $915,000 after acquiring an additional 65,994 shares during the last quarter. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.